Trials / Completed
CompletedNCT02154347
Post-marketing Clinical Trial of KAD-1229 in Patients With Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 178 (actual)
- Sponsor
- Kissei Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- —
Summary
The purpose of this study is to evaluate the safety and efficacy of KAD-1229 as combination therapy with insulin for 16 weeks and up to 52 weeks administration in patients with type 2 Diabetes Mellitus who show inadequate glycemic control with diet, and insulin monotherapy, or insulin and oral hypoglycemic agent.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KAD-1229 | |
| DRUG | Placebo | |
| DRUG | Insulin |
Timeline
- Primary completion
- 2016-07-01
- First posted
- 2014-06-03
- Last updated
- 2019-09-06
- Results posted
- 2019-09-06
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02154347. Inclusion in this directory is not an endorsement.